As proof-of-principle, a recent clinical study of apelin in PAH showed that administration of apelin provided significant additive benefit, on top of concomitant PDE5 inhibitor therapy, in decreasing pulmonary vascular resistance, and increasing cardiac output and stroke volume (Brash et al., 2018). This evidence concerns the gene APLN and pulmonary arterial hypertension.